Non-Hodgkin’s Lymphoma And Chronic Lymphocytic Leukemia – Current Treatment – Detailed, Expanded Analysis (US): Treatment Sequencing

KEY BENEFITS AND USES

  • Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
  • Drill down into physicians’ treatment sequences and understand which drugs to position against or how to defend share.
  • Identify untapped treatment scenarios and key competitors to aid trial design.
  • Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
  • Discover untapped populations to expand product share and drive strategic decisions.

QUESTIONS ANSWERED

  • Where is my product positioned versus competitors’ products in the treatment journey?
  • What are physicians’ most frequent treatment sequences? Who is benefiting, and how can I defend my asset’s share and position?
  • What are the market-relevant treatment scenarios according to oncology experts?
  • Where are the untapped business opportunities that I can capitalize on?
  • How can I optimize trial design and ensure a competitive edge for my pipeline asset?

PRODUCT DESCRIPTION

Treatment Sequencing provides disease-specific sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians.

GEOGRAPHY

United States

PRIMARY MARKET RESEARCH

Survey of ~100 U.S. hematologist-oncologists

Table of contents

  • Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Current Treatment - Detailed, Expanded Analysis (US): Treatment Sequencing
    • Treatment Sequencing Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia US August 2021

launch Related Market Assessment Reports